Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion
I'm PortAI, I can summarize articles.
WuXi Biologics (Cayman) Inc. expects its revenue for 2025 to rise by 16.7% to RMB21.79 billion, with a gross profit margin projected to increase by 5 percentage points to 46.0%. Adjusted gross profit is anticipated to reach approximately RMB10.64 billion, reflecting a year-on-year growth of 25.5%. The company credits this growth to the ramp-up of its European manufacturing facility, cost savings, efficiency improvements, and investment gains.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments